Showing 2381-2390 of 6036 results for "".
- Haag-Streit Announces the Launch of the Ellex Eye Prime in UKhttps://modernod.com/news/haag-streit-uk-announces-the-launch-of-the-ellex-eye-prime/2476912/Haag-Streit UK (HS-UK) has announced the launch of the Eye Prime diagnostic ultrasound system in the UK. The Eye Prime is the next-generation ultrasound solution from Ellex. It features the industry’s first and only “six-ring phased annular array technology,” delivering crisp, high-de
- Ophtec’s Preloaded Capsular Tension Ring Ringject Receives Approval in Chinahttps://modernod.com/news/ophtecs-preloaded-capsular-tension-ring-ringject-receive-approval-in-china/2476275/Ophtec was granted CFDA approval for the preloaded capsular tension ring (CTR) Ringject in China. Ringject is a preloaded, single use capsular tension ring designed to be self-loading for surgical convenience. CTRs were originally introduced to strengthen the zonule in eyes with zonular de
- Oculogica Receives FDA Marketing Approval for EyeBOX, the First Noninvasive, Baseline-Free Test for Concussionhttps://modernod.com/news/oculogica-receives-fda-marketing-approval-for-eyebox-the-first-noninvasive-baseline-free-test-for-concussion/2476218/Oculogica announced that the FDA granted their De Novo request for the commercialization of EyeBOX, the first noninvasive, baseline-free tool to aid in the diagnosis of concussion. Oculogica plans to market the device for use in pediatrics ages 5 and older and adults up to 67 years o
- Oculis In-Licenses Phase 2 Topical Anti-TNF Alpha Antibody From Novartishttps://modernod.com/news/oculis-in-licenses-phase-2-topical-anti-tnf-alpha-antibody-from-novartis/2476220/Oculis has entered into an agreement to in-license a novel topical anti-TNF alpha antibody from Novartis. Terms of the deal were not disclosed. The compound, named LME 636, is based on a proprietary single-chain antibody fragment technology specifically de
- Novaliq Announces Positive Topline Results for Its SEECASE Phase 2 Trial of NOV03 for the Treatment of Patients with Dry Eye Diseasehttps://modernod.com/news/novaliq-announces-positive-topline-results-for-its-seecase-phase-2-trial-of-nov03-for-the-treatment-of-patients-with-dry-eye-disease/2479732/Novaliq announces positive topline results for its SEECASE phase 2 clinical trial of NOV03 for the treatment of dry eye disease (DED) in more than 300 patients. NOV03 (100% perfluorohexyloctane) is a preservative-free ophthalmic solution and the first drug developed to treat evaporative DE
- RGN-259 (Tβ4) Improves Clinically Important Dry Eye Efficacies in Comparison with Prescription Drugshttps://modernod.com/news/rgn-259-tceb24-improves-clinically-important-dry-eye-efficacies-in-comparison-with-prescription-drugs/2480019/RegeneRx Biopharmaceuticals announced that a new study was published comparing RGN-259 with currently approved prescription products for dry eye syndrome (DES). In the study, researchers demonstrated that after 10 days of treatment RGN-259 performed equal to or better than cyclosporine A (Restasi
- Oculus Incorporates Oculus Brasil in São Paulohttps://modernod.com/news/oculus-incorporates-oculus-brasil-in-sao-paulo/2480050/Oculus Optikgeräte, Germany, has incorporated Oculus Brasil Comercio Importação Exportação e Serviços de Equipamentos Médicos LTDA as its 10th international subsidiary. Located in São Paulo, Oculus Brasil will support new and existing customers throughout Brazil. Oculus Optikger
- NuSight Medical Launches NuLids for the Treatment of Dry Eyehttps://modernod.com/news/nusight-medical-launches-nulids-for-the-treatment-of-dry-eye/2480078/NuSight Medical has introduced The NuLids System, a doctor-prescribed, home-use medical device that efficiently treats dry eye by gently stimulating, de-capping, and rejuvenating the meibomian glands to a healthier state. The system was introduced at the American Optometric Association mee
- Avisi Technologies Announces Positive 12-Month Clinical Data on VisiPlate Aqueous Shunthttps://modernod.com/news/avisi-technologies-announces-positive-12-month-clinical-data-on-visiplate-aqueous-shunt/2484305/Avisi Technologies announced positive 12-month clinical data on its VisiPlate Aqueous Shunt from the VITA trial during the 2025 AAO Annual Meeting. The study was presented by Jonathan Myers, MD, chief of the glaucoma service at Wills Eye Hospital, Thomas Jefferson University, in Philadelphia.
- Maura Sweeney Appointed Chief Operating Officer at Lighthouse Guildhttps://modernod.com/news/maura-sweeney-appointed-chief-operating-officer-at-lighthouse-guild-1/2482720/Lighthouse Guild announces the appointment of Maura Sweeney as Chief Operating Officer, effective April 1, 2025. Ms. Sweeney has been a vital part of Lighthouse Guild since 2010, most recently serving as Chief Program and Services Officer. A seasoned health care professional, she brings